

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
October 25, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

October 25, 2007  
Date of Report (Date of earliest event reported)

ANTIGENICS INC.

-----  
(Exact name of registrant as specified in its charter)

DELAWARE

000-29089

06-1562417

-----  
(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

162 Fifth Avenue, Suite 900  
New York, NY

(Address of principal executive offices)

10010  
(Zip Code)

212-994-8200

(Registrant's telephone number, including area code)  
-----

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On October 25, 2007, Antigenics Inc. announced that follow-up data from a Phase 1/2 investigator-sponsored trial of the company's investigational cancer vaccine Oncophage(R) (vitespen) in recurrent, high-grade glioma showed that 11 out of 12 patients exceeded the historical median benchmark of 6.5 months

## Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

survival from time of recurrence. The results from the investigator-initiated National Institutes of Health-sponsored study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco (UCSF), were presented at the International Conference on Molecular Targets and Cancer Therapeutics, jointly sponsored by the American Association for Cancer Research, National Cancer Institute and European Organization for Research and Treatment of Cancer (AACR-NCI-EROTC; abstract # 963).

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

### Item 9.01 Financial Statements and Exhibits

#### (d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated October 25, 2007

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: October 25, 2007

By: /s/ Garo H. Armen

-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

### EXHIBIT INDEX

Exhibit No. -----	Description of Exhibit -----
99.1	Press Release dated October 25, 2007